{"id":183345,"date":"2024-02-22T09:23:27","date_gmt":"2024-02-22T15:23:27","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/02\/car-t-cell-therapy-appears-to-be-feasible-safe-for-autoimmune-diseases"},"modified":"2024-02-22T09:23:27","modified_gmt":"2024-02-22T15:23:27","slug":"car-t-cell-therapy-appears-to-be-feasible-safe-for-autoimmune-diseases","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/02\/car-t-cell-therapy-appears-to-be-feasible-safe-for-autoimmune-diseases","title":{"rendered":"CAR T-cell therapy appears to be feasible, safe for autoimmune diseases"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/car-t-cell-therapy-appears-to-be-feasible-safe-for-autoimmune-diseases2.jpg\"><\/a><\/p>\n<p>CD19 chimeric antigen receptor (CAR) T-cell therapy seems feasible, safe, and efficacious for patients with different autoimmune diseases, according to a <a href=\"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2308917\">study<\/a> published in the Feb. 22 issue of the New England Journal of Medicine.<\/p>\n<p>Fabian M\u00fcller, M.D., from the Friedrich-Alexander University Erlangen-N\u00fcrnberg in Germany, and colleagues examined patients with severe systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, or systemic sclerosis (eight, three, and four patients, respectively) who received a single infusion of CD19 CAR T-cells after fludarabine and cyclophosphamide preconditioning.<\/p>\n<p>Efficacy was assessed up to two years after CAR T-cell infusion, measured using the Definition of Remission in SLE (DORIS) <a href=\"https:\/\/medicalxpress.com\/tags\/remission\/\" rel=\"tag\" class=\"\">remission<\/a> criteria, American College of Rheumatology-European League against Rheumatism (ACR-EULAR) major clinical response, and the score on the European Scleroderma Trials and Research Group (EUSTAR) activity index.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>CD19 chimeric antigen receptor (CAR) T-cell therapy seems feasible, safe, and efficacious for patients with different autoimmune diseases, according to a study published in the Feb. 22 issue of the New England Journal of Medicine. Fabian M\u00fcller, M.D., from the Friedrich-Alexander University Erlangen-N\u00fcrnberg in Germany, and colleagues examined patients with severe systemic lupus erythematosus (SLE), [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-183345","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/183345","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=183345"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/183345\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=183345"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=183345"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=183345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}